Abstracts tagged "infliximab and psoriatic arthritis"

Abstract Number: 676 • 2015 ACR/ARHP Annual Meeting
What Proportion of Patients with Psa Fail to Achieve MDA Based on Patient Reported Outcomes? an Analysis from a Prospective, Observational Registry
Proton Rahman¹, J Antonio Avina-Zubieta², Regan Arendse³, William G Bensen⁴, Philip Baer⁵, John Kelsall⁶, Michael Starr⁷, Jacqueline Stewart⁸, Dalton Sholter⁹, Michel Zummer¹⁰, Leo Picard¹¹, Emmanouil Rampakakis¹², Eliofotisti Psaradellis¹³, Karina Maslova¹⁴, Allen J Lehman¹⁴, Francois Nantel^15,16, Cathy Tkaczyk¹⁷ and Brendan Osborne¹⁷, ¹Medicine, Memorial University, St John's, NF, Canada, ²Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada, ³University of Saskatchewan, Saskatoon, ON, Canada, ⁴St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Section on Rheumatology, Ontario Medical Association/Journal of the Canadian Rheumatology Association, Toronto, ON, Canada, ⁶Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁷Rheumatology, McGill University, Montreal, QC, Canada, ⁸Penticton Regional Hospital, Penticton, BC, Canada, ⁹Rheumatology Associates, Edmonton, AB, Canada, ¹⁰Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, ¹¹Rhumatologie Moncton, Moncton, NB, Canada, ¹²JSS Medical Research, St-Laurent, QC, Canada, ¹³JSS Medical Research, Montreal, QC, Canada, ¹⁴Janssen Inc., Toronto, ON, Canada, ¹⁵Schering Plough Canada Inc., Janssen Inc., Kirkland, QC, QC, Canada, ¹⁶19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹⁷Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Recent treat-to-target guidelines in PsA recommend that minimal disease activity (MDA) is achieved as early as possible. Patient reported outcomes (PROs) have been criticized…
Abstract Number: 2484 • 2013 ACR/ARHP Annual Meeting
Immunogenicity Of TNFα Blockers In Patients With Psoriatic Arthritis
Michael Zisapel Zisapel¹, Noa Madar-Balakirsi², Hagit Padova³, Irena Wigler⁴, Daphna Paran⁵, Uri Arad⁴, Dan Caspi⁶ and Ori Elkayam⁷, ¹Rheumatology, Tel Aviv Medical Centet, Tel Aviv, Israel, ²Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel, ³Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁴Department of Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁵Rheumatology, Tel Aviv Sourasky Medical Ctr, Tel-Aviv university, Tel Aviv, Israel, ⁶Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁷Rheumatology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel- Aviv, Israel
Background/Purpose: TNFα blockers have been shown to produce immunogenecity in patients with rheumatoid arthritis, spondyloarthrritis and inflammatory bowel diseases. Data on the induction of anti-drug…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].